HomeNASDAQ:MRNA

NASDAQ:MRNA

Moderna Advances Pipeline and Secures Blackstone Funding

Moderna Advances Pipeline and Secures Blackstone Funding

March 29, 2024

Moderna Stock Surges 9% as Neoantigen Therapy’s Phase II/III Study Progresses

Moderna Stock Surges 9% as Neoantigen Therapy’s Phase II/III Study Progresses

March 12, 2024

Moderna Exceeds Expectations in Q4 Earnings and Revenue, Maintains Outlook

Moderna Exceeds Expectations in Q4 Earnings and Revenue, Maintains Outlook

February 22, 2024

Moderna and Merck Embark on Second Late-Stage Trial for Cancer Therapy

Moderna and Merck Embark on Second Late-Stage Trial for Cancer Therapy

December 12, 2023

Moderna Collaborates with Immatics to Advance Cancer Therapies

Moderna Collaborates with Immatics to Advance Cancer Therapies

September 12, 2023

Moderna Stock Rose After It Topped Q1 2023 Vaccine Demand Expectations

Moderna Stock Rose After It Topped Q1 2023 Vaccine Demand Expectations

May 4, 2023

Moderna stock drops 5% on mixed flu vaccine findings, but analysts remain optimistic

Moderna stock drops 5% on mixed flu vaccine findings, but analysts remain optimistic

March 1, 2023

Moderna Stock Fell as Concerns About the Pandemic and the Future of the COVID Vaccine Were Highlighted

Moderna Stock Fell as Concerns About the Pandemic and the Future of the COVID Vaccine Were Highlighted

February 26, 2023